IL6 and necrotizing enterocolitis: A18 administration significantly reduced NEC severity when administered orally to wild-type but not Ahr-/- mice, as manifest by improved histology (Fig. 6h), improved NEC severity score (Fig. 6i), and reduced expression of Il6 (Fig. 6j) and Tnf-α (Fig. 6k).